Julien G.
- Country
- France
- Department
- MEDICAL ONCOLOGY
Research Overview
- Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine or Investigator's Choice Chemotherapy in Patients with FRα-High or FRα-Low Platinum-Resistant Epithelial Ovarian Cancer
- Study of Inavolisib with Trastuzumab and Pertuzumab as Maintenance Therapy in Patients with HER2‑Positive PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer
- De-escalation of endocrine therapy in postmenopausal women with low-risk HR+ HER2- low Luminal A early breast cancer: a single-arm study of omission versus combination therapy
Data & Insights
Has run more than one trial at 404 of 753 partner sites.
Specializations
Breast Cancer Research
Specializes in investigating therapeutic approaches for various breast cancer subtypes, with particular focus on hormone receptor-positive, HER2-positive, and triple-negative breast cancer.
- Advanced metastatic disease management
- Early-stage treatment optimization
- Targeted therapy development
Explores innovative treatment combinations including immunotherapy, targeted agents, and hormone therapy.
Precision Medicine Applications
Focuses on developing personalized treatment strategies using molecular biomarkers and circulating tumor DNA for cancer detection and monitoring.
- Treatment response monitoring
- Early relapse detection
- Biomarker-guided therapy
Implements novel approaches for treatment optimization based on molecular characteristics.
Gynecologic Oncology
Conducts research in advanced ovarian cancer and related malignancies, investigating new therapeutic strategies and maintenance treatments.
- First-line treatment optimization
- Maintenance therapy innovation
- Combination therapy approaches
Evaluates novel drug combinations and treatment sequences for improved patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.